Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bevacizumab biosimilar by Innovent Biologics for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal...
Bevacizumab biosimilar by Shanghai Henlius Biotech for Hepatocellular Carcinoma: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Hepatocellular Carcinoma. According to...
Bevacizumab biosimilar by Chia Tai Tianqing Pharmaceutical Group for Cervical Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Cervical Cancer....
Bevacizumab biosimilar by R-Pharm for Ovarian Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Bevacizumab biosimilar by R-Pharm for Metastatic Colorectal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
Bevacizumab biosimilar by R-Pharm for Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
Bevacizumab biosimilar by Essex Bio-Technology for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Essex Bio-Technology and currently in Phase III for Wet (Neovascular / Exudative) Macular...
Bevacizumab biosimilar by R-Pharm for Non-Small Cell Lung Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Bevacizumab biosimilar by R-Pharm for Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
Bevacizumab biosimilar by Curateq Biologics for Peritoneal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Peritoneal Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Metastatic Colorectal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Metastatic Colorectal Cancer. According to...
Bevacizumab biosimilar by Curateq Biologics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Kidney Cancer (Renal Cell Cancer)....
Bevacizumab biosimilar by Curateq Biologics for Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Glioblastoma Multiforme (GBM). According to...
Bevacizumab biosimilar by Curateq Biologics for Cervical Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Cervical Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Ovarian Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Ovarian Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Breast Cancer. According to GlobalData,...
Bevacizumab biosimilar by Innovent Biologics for Endometrial Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData,...
Bevacizumab biosimilar by Bio-Thera Solutions for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...
Bevacizumab biosimilar by Biocad for Non-Small Cell Lung Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Biocad and currently in Phase III for Non-Small Cell Lung Cancer. According to...